SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    John R. Foster, Garry Lund, Svetlana Sapelnikova, D. Lorne Tyrrell, Norman M. Kneteman, Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies, Xenobiotica, 2014, 44, 2, 109

    CrossRef

  2. 2
    Andrew Maynard, Renae M. Crosby, Byron Ellis, Robert Hamatake, Zhi Hong, Brian A. Johns, Kirsten M. Kahler, Cecilia Koble, Anna Leivers, Martin R. Leivers, Amanda Mathis, Andrew J. Peat, Jeffrey J. Pouliot, Christopher D. Roberts, Vicente Samano, Rachel M. Schmidt, Gary K. Smith, Andrew Spaltenstein, Eugene L. Stewart, Pia Thommes, Elizabeth M. Turner, Christian Voitenleitner, Jill T. Walker, Greg Waitt, Jason Weatherhead, Kurt Weaver, Shawn Williams, Lois Wright, Zhiping Z. Xiong, David Haigh, J. Brad Shotwell, Discovery of a Potent Boronic Acid Derived Inhibitor of the HCV RNA-Dependent RNA Polymerase, Journal of Medicinal Chemistry, 2014, 57, 5, 1902

    CrossRef

  3. 3
    Kevin X. Chen, Srikanth Venkatraman, Gopinadhan N. Anilkumar, Qingbei Zeng, Charles A. Lesburg, Bancha Vibulbhan, Francisco Velazquez, Tin-Yau Chan, Frank Bennet, Yueheng Jiang, Patrick Pinto, Yuhua Huang, Oleg Selyutin, Sony Agrawal, Hsueh-Cheng Huang, Cheng Li, Kuo-Chi Cheng, Neng-Yang Shih, Joseph A. Kozlowski, Stuart B. Rosenblum, F. George Njoroge, Discovery of SCH 900188: A Potent Hepatitis C Virus NS5B Polymerase Inhibitor Prodrug As a Development Candidate, ACS Medicinal Chemistry Letters, 2014, 5, 3, 244

    CrossRef

  4. 4
    John F. Miller, Pek Y. Chong, J. Brad Shotwell, John G. Catalano, Vincent W.-F. Tai, Jing Fang, Anna L. Banka, Christopher D. Roberts, Michael Youngman, Huichang Zhang, Zhiping Xiong, Amanda Mathis, Jeffery J. Pouliot, Robert K. Hamatake, Daniel J. Price, John W. Seal, Lisa L. Stroup, Katrina L. Creech, Luz H. Carballo, Dan Todd, Andrew Spaltenstein, Sylvia Furst, Zhi Hong, Andrew J. Peat, Hepatitis C Replication Inhibitors That Target the Viral NS4B Protein, Journal of Medicinal Chemistry, 2014, 57, 5, 2107

    CrossRef

  5. 5
    Srikanth Venkatraman, Francisco Velazquez, Stephen Gavalas, Wanli Wu, Kevin X. Chen, Anilkumar G. Nair, Frank Bennett, Yuhua Huang, Patrick Pinto, Yueheng Jiang, Oleg Selyutin, Bancha Vibulbhan, Qingbei Zeng, Charles Lesburg, Jose Duca, Larry Heimark, Hsueh-Cheng Huang, Sony Agrawal, Chuan-kui Jiang, Eric Ferrari, Cheng Li, Joseph Kozlowski, Stuart Rosenblum, Neng-Yang Shih, F. George Njoroge, Optimization of potency and pharmacokinetics of tricyclic indole derived inhibitors of HCV NS5B polymerase. Identification of ester prodrugs with improved oral pharmacokinetics, Bioorganic & Medicinal Chemistry, 2014, 22, 1, 447

    CrossRef

  6. 6
    Y. Wen, C. Cheng Kao, The hepatitis C virus core protein can modulate RNA-dependent RNA synthesis by the 2a polymerase, Virus Research, 2014, 189, 165

    CrossRef

  7. 7
    Helen Kylefjord, Axel Danielsson, Susanne Sedig, Oscar Belda, Daniel Wiktelius, Lotta Vrang, Paul Targett-Adams, Transient replication of a hepatitis C virus genotype 1b replicon chimera encoding NS5A-5B from genotype 3a, Journal of Virological Methods, 2014, 195, 156

    CrossRef

  8. 8
    Eric Lawitz, Maribel Rodriguez-Torres, Albrecht Stoehr, Edward J. Gane, Lawrence Serfaty, Sanhita Bhanja, Richard J. Barnard, Di An, Jacqueline Gress, Peggy Hwang, Niloufar Mobashery, A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment, Journal of Hepatology, 2013, 59, 1, 11

    CrossRef

  9. 9
    Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Norio Itokawa, Yoshiyuki Narahara, Katsuhisa Nakatsuka, Satomi Hashimoto, Takeshi Fukuda, Yoko Matsushita, Hideko Kidokoro, Tamaki Kobayashi, Hidenori Kanazawa, Choitsu Sakamoto, Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b, Journal of Gastroenterology and Hepatology, 2013, 28, 1
  10. 10
    Srikanth Venkatraman, Francisco Velazquez, Stephen Gavalas, Wanli Wu, Kevin X. Chen, Anilkumar G. Nair, Frank Bennett, Yuhua Huang, Patrick Pinto, Yueheng Jiang, Oleg Selyutin, Bancha Vibulbhan, Qingbei Zeng, Charles Lesburg, Jose Duca, Hsueh-Cheng Huang, Sony Agrawal, Chuan-kui Jiang, Eric Ferrari, Cheng Li, Joseph Kozlowski, Stuart Rosenblum, Neng-Yang Shih, F. George Njoroge, Discovery of novel tricyclic indole derived inhibitors of HCV NS5B RNA dependent RNA polymerase, Bioorganic & Medicinal Chemistry, 2013, 21, 7, 2007

    CrossRef

  11. 11
    Sylvie Lagaye, Hong Shen, Géraldine Rousseau, Stanislas Pol, Major models of HCV infection, Future Virology, 2013, 8, 5, 493

    CrossRef

  12. 12
    William E. Delaney, Molecular virology of chronic hepatitis B and C: Parallels, contrasts and impact on drug development and treatment outcome, Antiviral Research, 2013, 99, 1, 34

    CrossRef

  13. 13
    Alessio Aghemo, Raffaele De Francesco, New horizons in hepatitis C antiviral therapy with direct-acting antivirals, Hepatology, 2013, 58, 1
  14. 14
    Christian M. Lange, Stefan Zeuzem, Perspectives and challenges of interferon-free therapy for chronic hepatitis C, Journal of Hepatology, 2013, 58, 3, 583

    CrossRef

  15. 15
    Yasir Waheed, Attya Bhatti, Muhammad Ashraf, RNA dependent RNA polymerase of HCV: A potential target for the development of antiviral drugs, Infection, Genetics and Evolution, 2013, 14, 247

    CrossRef

  16. 16
    Romain Haudecoeur, Marine Peuchmaur, Abdelhakim Ahmed-Belkacem, Jean-Michel Pawlotsky, Ahcène Boumendjel, Structure–Activity Relationships in the Development of Allosteric Hepatitis C Virus RNA-Dependent RNA Polymerase Inhibitors: Ten Years of Research, Medicinal Research Reviews, 2013, 33, 5
  17. 17
    Kevin X. Chen, Charles A. Lesburg, Bancha Vibulbhan, Weiying Yang, Tin-Yau Chan, Srikanth Venkatraman, Francisco Velazquez, Qingbei Zeng, Frank Bennett, Gopinadhan N. Anilkumar, Jose Duca, Yueheng Jiang, Patrick Pinto, Li Wang, Yuhua Huang, Oleg Selyutin, Stephen Gavalas, Haiyan Pu, Sony Agrawal, Boris Feld, Hsueh-Cheng Huang, Cheng Li, Kuo-Chi Cheng, Neng-Yang Shih, Joseph A. Kozlowski, Stuart B. Rosenblum, F. George Njoroge, A Novel Class of Highly Potent Irreversible Hepatitis C Virus NS5B Polymerase Inhibitors, Journal of Medicinal Chemistry, 2012, 55, 5, 2089

    CrossRef

  18. 18
    C. Kondo, M. Atsukawa, A. Tsubota, N. Itokawa, T. Fukuda, Y. Matsushita, H. Kidokoro, T. Kobayashi, Y. Narahara, K. Nakatsuka, H. Kanazawa, C. Sakamoto, An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin, Journal of Viral Hepatitis, 2012, 19, 9
  19. 19
    Hideyuki Konishi, Koichi Okamoto, Yusuke Ohmori, Hitoshi Yoshino, Hiroshi Ohmori, Motooki Ashihara, Yuichi Hirata, Atsunori Ohta, Hiroshi Sakamoto, Natsuko Hada, Asao Katsume, Michinori Kohara, Kazumi Morikawa, Takuo Tsukuda, Nobuo Shimma, Graham R. Foster, William Alazawi, Yuko Aoki, Mikio Arisawa, Masayuki Sudoh, An orally available, small-molecule interferon inhibits viral replication, Scientific Reports, 2012, 2,

    CrossRef

  20. 20
    Jens Bukh, Animal Models for the Study of Hepatitis C Virus Infection and Related Liver Disease, Gastroenterology, 2012, 142, 6, 1279

    CrossRef

  21. 21
    Christoph Sarrazin, Christophe Hézode, Stefan Zeuzem, Jean-Michel Pawlotsky, Antiviral strategies in hepatitis C virus infection, Journal of Hepatology, 2012, 56, S88

    CrossRef

  22. 22
    Marina M. May, Dirk Brohm, Axel Harrenga, Tobias Marquardt, Bernd Riedl, Joerg Kreuter, Holger Zimmermann, Helga Ruebsamen-Schaeff, Andreas Urban, Discovery of substituted N-phenylbenzenesulphonamides as a novel class of non-nucleoside hepatitis C virus polymerase inhibitors, Antiviral Research, 2012, 95, 2, 182

    CrossRef

  23. 23
    Abdelrahman S. Mayhoub, Hepatitis C RNA-dependent RNA polymerase inhibitors: A review of structure–activity and resistance relationships; different scaffolds and mutations, Bioorganic & Medicinal Chemistry, 2012, 20, 10, 3150

    CrossRef

  24. 24
    Philip Roelandt, Susan Obeid, Jan Paeshuyse, Jolien Vanhove, Alfons Van Lommel, Yaakov Nahmias, Frederik Nevens, Johan Neyts, Catherine M Verfaillie, Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus, Journal of Hepatology, 2012, 57, 2, 246

    CrossRef

  25. 25
    Norman M. Kneteman, Sonal Asthana, Jamie Lewis, Chelcey Dibben, Donna Douglas, Mahra Nourbakhsh, Lorne J. Tyrrell, Garry Lund, Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection, Liver Transplantation, 2012, 18, 1
  26. 26
    S. Chevaliez, C. Hézode, J.-M. Pawlotsky, Stratégies antivirales dans l’hépatite chronique C, Journal des Anti-infectieux, 2012, 14, 2, 78

    CrossRef

  27. 27
    Kevin X. Chen, Bancha Vibulbhan, Weiying Yang, Mousumi Sannigrahi, Francisco Velazquez, Tin-Yau Chan, Srikanth Venkatraman, Gopinadhan N. Anilkumar, Qingbei Zeng, Frank Bennet, Yueheng Jiang, Charles A. Lesburg, Jose Duca, Patrick Pinto, Stephen Gavalas, Yuhua Huang, Wanli Wu, Oleg Selyutin, Sony Agrawal, Boris Feld, Hsueh-Cheng Huang, Cheng Li, Kuo-Chi Cheng, Neng-Yang Shih, Joseph A. Kozlowski, Stuart B. Rosenblum, F. George Njoroge, Structure–Activity Relationship (SAR) Development and Discovery of Potent Indole-Based Inhibitors of the Hepatitis C Virus (HCV) NS5B Polymerase, Journal of Medicinal Chemistry, 2012, 55, 2, 754

    CrossRef

  28. 28
    Kazuaki Chayama, C Nelson Hayes, Nobuhiko Hiraga, Hiromi Abe, Masataka Tsuge, Michio Imamura, Animal model for study of human hepatitis viruses, Journal of Gastroenterology and Hepatology, 2011, 26, 1
  29. 29
    Nam Doo Kim, Haarin Chun, Sang Jin Park, Jae Won Yang, Jong Woo Kim, Soon Kil Ahn, Discovery of novel HCV polymerase inhibitors using pharmacophore-based virtual screening, Bioorganic & Medicinal Chemistry Letters, 2011, 21, 11, 3329

    CrossRef

  30. 30
    S.-C. C. Sun, A. Bae, X. Qi, J. Harris, K. A. Wong, M. D. Miller, H. Mo, Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates, Journal of Viral Hepatitis, 2011, 18, 12
  31. 31
    J. Vermehren, C. Sarrazin, New HCV therapies on the horizon, Clinical Microbiology and Infection, 2011, 17, 2
  32. 32
    Johannes Vermehren, Christoph Sarrazin, New hepatitis C therapies in clinical development, European Journal of Medical Research, 2011, 16, 7, 303

    CrossRef

  33. 33
    Dange V. Kumar, Roopa Rai, Ken A. Brameld, John R. Somoza, Ravi Rajagopalan, James W. Janc, Yu M. Xia, Tony L. Ton, Michael B. Shaghafi, Huiyong Hu, Isabelle Lehoux, Nhat To, Wendy B. Young, Michael J. Green, Quinolones as HCV NS5B polymerase inhibitors, Bioorganic & Medicinal Chemistry Letters, 2011, 21, 1, 82

    CrossRef

  34. 34
    Debasis Das, Jian Hong, Shu-Hui Chen, Guangyi Wang, Leonid Beigelman, Scott D. Seiwert, Brad O. Buckman, Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors, Bioorganic & Medicinal Chemistry, 2011, 19, 16, 4690

    CrossRef

  35. 35
    Marina M. May, Heike Lorengel, Joerg Kreuter, Holger Zimmermann, Helga Ruebsamen-Schaeff, Andreas Urban, RNA-dependent RNA polymerases from different hepatitis C virus genotypes reveal distinct biochemical properties and drug susceptibilities, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2011, 1814, 10, 1325

    CrossRef

  36. 36
    Tianmin Zhu, Mahdi B. Fawzi, Michael Flint, Fangming Kong, Jan Szeliga, Russ Tsao, Anita Y.M. Howe, Weitao Pan, Design and synthesis of HCV agents with sequential triple inhibitory potentials, Bioorganic & Medicinal Chemistry Letters, 2010, 20, 17, 5212

    CrossRef

  37. 37
    Cliff C. Cheng, Gerald W. Shipps, Zhiwei Yang, Noriyuki Kawahata, Charles A. Lesburg, José S. Duca, Jamie Bandouveres, Jack D. Bracken, Chuan-kui Jiang, Sony Agrawal, Eric Ferrari, H.-C. Huang, Inhibitors of hepatitis C virus polymerase: Synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides, Bioorganic & Medicinal Chemistry Letters, 2010, 20, 7, 2119

    CrossRef

  38. 38
    Hui Li, Stephanie T Shi, Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges, Future Medicinal Chemistry, 2010, 2, 1, 121

    CrossRef

  39. 39
    N. Kamiya, E. Iwao, N. Hiraga, M. Tsuge, M. Imamura, S. Takahashi, S. Miyoshi, C. Tateno, K. Yoshizato, K. Chayama, Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor, Journal of General Virology, 2010, 91, 7, 1668

    CrossRef

  40. 40
    Christoph Sarrazin, Stefan Zeuzem, Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection, Gastroenterology, 2010, 138, 2, 447

    CrossRef

  41. You have free access to this content41
    C. M. Lange, C. Sarrazin, S. Zeuzem, Review article: specifically targeted anti-viral therapy for hepatitis C – a new era in therapy, Alimentary Pharmacology & Therapeutics, 2010, 32, 1
  42. 42
    Tanya Parkinson, David C Pryde, Small molecule drug discovery for Dengue and West Nile viruses: applying experience from hepatitis C virus, Future Medicinal Chemistry, 2010, 2, 7, 1181

    CrossRef

  43. 43
    Dawn McDowell Torres, Update on Specifically Targeted Antiviral Therapy for Hepatitis C Infection: Progress and Pitfalls on the Road to Viral Eradication, Current Hepatitis Reports, 2010, 9, 3, 125

    CrossRef

  44. 44
    STUART C. RAY, DAVID L. THOMAS, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 2010,

    CrossRef

  45. 45
    Robert Chase, Angela Skelton, Ellen Xia, Stephanie Curry, Shaotang Liu, Patricia McMonagle, H.-C. Huang, Xiao Tong, A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors, Antiviral Research, 2009, 84, 2, 178

    CrossRef

  46. 46
    Andre Boonstra, Luc J. W. van der Laan, Thomas Vanwolleghem, Harry L. A. Janssen, Experimental models for hepatitis C viral infection, Hepatology, 2009, 50, 5
  47. 47
    Philip Meuleman, Geert Leroux-Roels, HCV Animal Models: A Journey of More than 30 Years, Viruses, 2009, 1, 2, 222

    CrossRef

  48. 48
    James R. Burton, Gregory T. Everson, HCV NS5B Polymerase Inhibitors, Clinics in Liver Disease, 2009, 13, 3, 453

    CrossRef

  49. 49
    Michael G. Hughes, Hugo R. Rosen, Human liver transplantation as a model to study hepatitis C virus pathogenesis, Liver Transplantation, 2009, 15, 11
  50. 50
    Naoya Sakamoto, Mamoru Watanabe, New therapeutic approaches to hepatitis C virus, Journal of Gastroenterology, 2009, 44, 7, 643

    CrossRef

  51. 51
    Javier de Vicente, Robert T. Hendricks, David B. Smith, Jay B. Fell, John Fischer, Stacey R. Spencer, Peter J. Stengel, Peter Mohr, John E. Robinson, James F. Blake, Ramona K. Hilgenkamp, Calvin Yee, George Adjabeng, Todd R. Elworthy, Jim Li, Beihan Wang, Joe T. Bamberg, Seth F. Harris, April Wong, Vincent J.P. Leveque, Isabel Najera, Sophie Le Pogam, Sonal Rajyaguru, Gloria Ao-Ieong, Ludmila Alexandrova, Susan Larrabee, Michael Brandl, Andrew Briggs, Sunil Sukhtankar, Robert Farrell, Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: Structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides, Bioorganic & Medicinal Chemistry Letters, 2009, 19, 19, 5652

    CrossRef

  52. 52
    Naoya Sakamoto, George Y Wu, Prospects for future therapy of HCV infection, Future Virology, 2009, 4, 5, 453

    CrossRef

  53. 53
    Nicholas A. Meanwell, John F. Kadow, Paul M. Scola, Annual Reports in Medicinal Chemistry Volume 44, 2009,

    CrossRef

  54. 54
    Nicholas A. Meanwell, Stanley V. D'Andrea, Christopher W. Cianci, Ira B. Dicker, Kap-Sun Yeung, Makonen Belema, Mark Krystal, Antiviral Drug Discovery,
  55. 55
    Lotte Coelmont, Leen Delang, Mathy Froeyen, Piet Herdewijn, Johan Neyts, Pharmacology and Mechanisms of Action of Antiviral Drugs: Polymerase Inhibitors,